Summary Sixty patients with locally advanced breast cancer, but with no evidence of distant metastases were randomised to receive primary endocrine therapy or chemotherapy after assessment and 'Trucut' biopsy of the primary tumour. After 12 weeks all patients were assessed. Eight out of 30 (27%) of the patients who received chemotherapy showed complete clinical regression of the primary cancer, eight patients' tumours had regressed by more than 50%, and ten showed a 25-50% reduction in bi-dimensional diameter. Only four (13%) patients' tumours failed to reduce in size. Seven patients were judged to require mastectomy at the end of the 12 week period of treatment with chemotherapy. In contrast, only three out of 30 (10%) patients receiving endocrine therapy showed a greater than 50% reduction in tumour size, and four patients had a 25-50% reduction at 12 weeks. The remaining patients' tumours either stabilised (12 patients) or enlarged (II patients). We conclude that primary chemotherapy in patients with primary breast cancer is more effective in rapidly reducing the size of the primary breast cancer than endocrine therapy (P = 0.001) and alters significantly the future management of these patients. However, at 65 weeks on completion of the follow-up, there is no significant difference in the number of patients' disease-free, locally or distant recurrent, or dead.
It is now generally agreed that conservative surgery by tumour excision is adequate for small cancers (TI and T2) but the management of patients with locally advanced carcinoma of the breast (T3, T4, NO-2 MO) presents a therapeutic challenge. Local radiation is only partially successful in controlling local tumour growth, with a local relapse rate in 36-72% of patients (Chu et al., 1984; Bruckman et al., 1979; Rubens et al., 1977) . Similarly conservative surgery has a similar local relapse rate (Fisher et al., 1985) . However, combination therapy of surgery and radiotherapy will control local disease (Veronesi et al., 1986) . The problem in the use of these modalities is the high rate of distant metastases uninfluenced by the control of the local disease in the short term.
Primary systemic treatment either with chemotherapy (Delena et al., 1981; Swain et al., 1987; Perloff et al., 1988) or endocrine therapy has been used in the past (Forrest et al., 1986; Gazet et al., 1988) . However, no randomised trial has been carried out to examine the relative merits of these two forms of systemic treatment when used in primary treatment of breast cancer in the short term, to influence the secondary treatment offered (surgery or radiotherapy) or in the long term, in the control and reduction of the incidence of metastatic disease.
The objective of this pilot study was 2-fold. First to compare the effectiveness of these two forms of treatment in the short term (12 weeks) and assess the impact of therapy on subsequent treatment and secondly to review the long term effect of therapy at 1 year post primary management (65 weeks). (Coombes et al., 1984; Stein et al., 1989) , or if premenopausal they received the luteinising hormone releasing hormone analogue goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Those randomised to receive chemotherapy received mitozantrone 7 mg m-2, and methotrexate 35 mg m-2, 3 weekly four times and mitomycin C 7 mg m2, 6 weekly, intravenously . There was no significant difference in the comparative age; menopausal status, TNM stage or histology in the two groups (Table I ).
All patients were assessed clinically at 4 weekly intervals. Tumour size was measured using calipers and compared with size at presentation. Response was defined by standard UICC criteria i.e. complete response was defined as no palpable mass, partial response as at least a 50% reduction in bidimensional diameter; stable disease either less than a 50% reduction in size or no change. Progressive disease was defined as a >25% increase in bidimensional diameter. To be considered a response, all measurements had to be confirmed as such in two subsequent separate clinical examinations at 4 weeks apart. At 12 weeks from the start of treatment, the patients were completed restaged and regraded according to the TNM Classification. The treatment policy adopted at this stage depended upon the TNM Classification and the wishes of the patient. Thus if the tumour was considered operable, patients with TI and T2 tumours were offered wide local excision; those with T3 and T4 tumours, radical mastectomy. If the tumour was inoperable, the patients were offered radical radiotherapy. Where no tumour was clinically palpable, patients were offered radiotherapy as an alternative to radical surgery.
Systemic treatment was only continued post-operatively if the primary tumour either responded or stabilised on systemic therapy: chemotherapy was continued for a further four cycles and endocrine therapy for a further 65 weeks. All patients were staged at the end of the first 12 weeks systemic therapy and/or at the end of the period of treatment. We examined side effects in both arms of the study. In the endocrine arm, only 5/30 patients had side effects (4-hydroxyandrostenedione: pain at injection site (n = 2); anaphylactoid reaction (n = 1); depression (n = 1). Goserelin: hot flushes (n = 1).
In patients who received chemotherapy 20/30 (67%) patients had side effects. Five patients had both nausea (WHO Grade I) and vomiting and a further four patients had nausea alone, one of which was WHO Grade II. Fourteen patients complained of lethargy, but only five were judged to have WHO GII lethargy. Stomatitis occurred in seven patients, but was WHO GII in only five patients, the remainder being WHO GI. One patient lost her taste and one developed sore eyes. Haematological toxicity was seen in five patients, with the white blood cell count falling to 2.5-3.5 x 109 1' in all five, and one patients's platelet count fell to 30 x 109 1'. All these five patients required between 20-30% dose reduction of chemotherapy, three after three cycles and two after five cycles.
None of the patients, however, developed septicaemia or bleeding episodes as a result of treatment.
We did not observe significant changes in the histological appearance using collective histology of the first and second biopsies obtained from the 23 patients who had surgery at 12 weeks.
The results at 65 weeks (Table IV) 
Discussion
This is the first reported trial to compare endocrine therapy and chemotherapy as primary treatment for locally advanced breast cancer. The principal finding is that 26/30 (90%) of patients randomised to receive combination chemotherapy showed a greater than 25% reduction in tumour volume at 12 weeks, and in eight patients, the tumour became impalpable. This therapy is well tolerated and resulted in significant myelosuppression in only five patients. Nausea and vomiting was well controlled in all but a minority of patients and alopecia was rarely seen. Twenty-nine of 30 patients completed their chemotherapy. As expected we observed a disappointing response to endocrine therapy as primary therapy, but the side effects were considered minimal. We did not observe the 'flare' occasionally seen in tamoxifen treated patients. The other advantage of 4-hydroxyandrostenedione was that the parenteral route of administration ensured that the patients actually received the treatment. However, only 21 of 30 patients completed their endocrine therapy due to change in treatment because of a change in disease status.
A possible explanation for the response rate is the rate of regression achieved by these different forms of treatment. Thus, endocrine therapy caused a slower reduction in size than chemotherapy, resulting in a response in 7/30 patients. We would expect that certainly a proportion of these patients would achieve partial and/or complete responses if treatment were continued, as we have observed in elderly patients (Gazet et ai., 1988) . However, we felt that definitive local treatment in these younger women could not be delayed longer than 12 weeks, and this is reflected in the higher rate of surgery in the endocrine arm of the study. However, at 65 weeks on completion of the trial, it is clear that there has been no significant difference between chemotherapy or endocrine therapy in relation to death, local recurrence, distant metastases and disease-free survival. Secondary surgery is higher in the chemotherapy arm.
Since this study began, we now have clear evidence that immunocytochemical prediction of response to endocrine therapy is reliable (Coombes et al., 1971 ). Using Trucut biopsy or fine needle aspiration material it is possible to determine the ER status by immunocytochemistry (ERICA) prior to treatment and this allows the preferred treatment, endocrine for ER positive and chemotherapy for ER negative patients, to be offered. In this study, we were able to measure ER by immunotochemistry in 13 patients before treatment and 12/13 showed >50% cells stained i.e. were ER positive (Coombes et al., 1987) . Amongst those 12 were the three responders to endocrine therapy. We were able to obtain six samples at 12 weeks for repeat ER and obtained similar results as the pretreatment estimation (both samples positive in five instances and both negative in a single case).
This pilot study has significant limitations in that the small number of patients studied means that we can only analyse response rates in the short term. Future trials will establish the impact of this form of primary systemic treatment on mortality from this disease. However, we feel that improved survival may result since it will be possible to select adjuvant therapy more accurately (a) selecting those that are endocrine sensitive using immunocytochemical tests, (b) by evaluating sensitivity of the primary tumour and thus response of micrometastases (McClelland et al., 1986; Coombes et al., 1986; Mansi et al., 1987) .
Our finding has two important clinical implications. Firstly, a significantly greater proportion of patients had conservative surgery or did not require surgery initially because of complete disappearance of the tumour in the chemotherapy arm of the study. Secondly, the degree of reduction in size achieved by primary chemotherapy may well reflect the sensitivity of micrometastases to systemic chemotherapy and this could be a highly significant prognostic feature in patients with breast cancer.
Further studies are now needed to define the role of immunocytochemistry in defining more accurately responders to endocrine therapy. More recently newer techniques which may provide additional information to ER have been adovated including (a) the presence of progesterone receptors that can now be measured immunocytochemically (PerrotApplanat et al., 1987; Berger et al., 1989) ; (b) the presence of the oestrogen-induced protein PS2 that is related to outcome (Rio et al., 1988; Skilton et al., 1989) and (c) the absence of EGFR which can also be detected immunocytochemically (Sainsbury et al., 1987) .
